CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
